Black Friday is Now! Don’t miss out on up to 60% OFF InvestingProCLAIM SALE

Britain approves Moderna's COVID-19 vaccine for use

Published 2021-01-08, 08:12 a/m
PFE
-

LONDON (Reuters) - Britain's medical regulator on Friday approved Moderna's COVID-19 vaccine for use, the health ministry said, adding that it had agreed to purchase an additional 10 million doses of the shot as it eyed a spring rollout of the shot.

Three COVID-19 vaccines have now been approved for use in Britain, with Pfizer//BioNTech's shot and one developed by Oxford University and AstraZeneca already being rolled out.

The Moderna shot is not expected to play a part in the first stage of Britain's vaccine rollout. Britain now has 17 million doses of Moderna's vaccine on order, and supplies will begin to be delivered to the UK from the spring once Moderna expands its production capability.

"We have already vaccinated nearly 1.5 million people across the UK and Moderna's vaccine will allow us to accelerate our vaccination programme even further once doses become available from the spring," health minister Matt Hancock said.

Britain was the first to approve Pfizer (NYSE:PFE)'s and AstraZeneca's vaccines as it bids to ramp up its vaccine rollout quickly but is behind some other major countries in giving the go-ahead to the Moderna shot.

Moderna's vaccine was 94% effective in preventing disease in late-stage clinical trials, and it has already been given regulatory approval for use in the United States, Canada, the European Union and Israel.

Britain is attempting to vaccinate the elderly, the vulnerable and frontline workers - around 15 million people - by mid-February, to ease a new strict lockdown imposed after a spike in cases to daily records.

Although Moderna's vaccine will not help meet that target, it will help ease supply constraints that Hancock has cited as being a limiting factor in the rollout.

"This is excellent news and a further crumb of comfort amid the huge levels of COVID-19 currently circulating around the UK," said Michael Head, Senior Research Fellow in Global Health at the University of Southampton.

"When these Moderna vaccines arrive, they will help to ease any bottlenecks or delays in the administration programme."

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.